GICS Sector : Industrials
Enovis Corporation operates as a medical technology company worldwide.It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger.
Enovis reported fourth quarter sales of $576 million, up 3% versus the prior year on a reported basis and 2% organic growth. For the year, the company generated $2.2 billion of sales, representing 7% reported growth. Adjusted gross margins increased to 61%, an improvement of 170 basis points, driven by favorable mix, ongoing productivity, and realized synergies in manufacturing and supply chain operations. The company delivered adjusted EBITDA margin of 17.9%, flat year-over-year, and adjusted earnings per share was $3.30, up 16%. The actual EPS for Q4 came out at $0.95, beating estimates of $0.81.
Publication Date: Mar -01
Enovis' Recon segment grew 8% for the year, outgrowing the market, while the Prevention and Recovery (P&R) segment grew at a mid-single-digit rate of 4%. The company's extremities business had a strong performance, with the foot and ankle market showing softness but Enovis outgrowing the market. The company has a multiyear pipeline of opportunities in extremities, with a focus on expanding into the sports medicine side of arthroplasty applications.
For 2026, Enovis expects revenues in the range of $2.31 billion to $2.37 billion, including mid-single-digit organic revenue growth of 4% to 6% year-over-year. The company expects free cash flow conversion as a percentage of adjusted net income to be 25% plus in 2026 and targets 70% to 80% free cash flow conversion over time. Analysts estimate next year's revenue growth at 5.4%, indicating a relatively stable outlook.
Enovis' current valuation metrics show a P/E Ratio of -1.22, a P/B Ratio of 0.97, and an EV/EBITDA of -1.84. The company's return on equity (ROE) is -54.42%, and its return on invested capital (ROIC) is -36.12%. The negative ratios are largely due to the company's historical performance and may not reflect its current trajectory. With a focus on debt reduction and disciplined capital allocation, Enovis aims to drive durable, profitable growth through innovation and a differentiated portfolio.
The company's One Enovis initiative aims to exploit synergies between Recon and P&R segments, both on the revenue and cost sides. Enovis has a rich pipeline of new product introductions, with 50% of its P&R portfolio growing mid-single digits or greater. The Optimus launch is expected to contribute to hip growth, with a long runway for growth driven by the Nebula and OrthoDrive products. The company's focus on commercial execution, geographic expansion, portfolio shaping, and evaluating its portfolio as a whole is expected to drive growth and margin expansion.
Royce Small-Cap Fund FY 2025: What Worked
Mar -09
Wall Street Analysts Think Enovis (ENOV) Could Surge 76.62%: Read This Before Placing a Bet
Mar -05
American Century Companies Inc. Sells 258,262 Shares of Enovis Corporation $ENOV
Mar -02
Enovis Q4 Earnings Call Highlights
Feb -28
Enovis Corporation (ENOV) Q4 2025 Earnings Call Transcript
Feb -27
One Fund Bet $5 Million on Enovis Stock Last Quarter. Shares Surged 14% Post-Earnings
Feb -26
Enovis (ENOV) Q4 Earnings Beat Estimates
Feb -26
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
Feb -26
Enovis Corporation's 9% growth in Prevention & Recovery is driven by increasing demand for orthopedic and spine solutions, expansion into emerging markets, strategic acquisitions, and investments in digital health technologies. Additionally, growing awareness of preventive care and rising healthcare expenditure contribute to the segment's growth.
Enovis Corporation's reconstructive segment growth of 11% is driven by increasing demand for orthopedic and spine procedures, expansion into emerging markets, and strategic acquisitions. Additionally, advancements in technology, such as robotic-assisted surgery and 3D printing, are fueling innovation and adoption. Furthermore, an aging population and rising prevalence of musculoskeletal disorders are contributing to the growth.
Enovis Corporation provides a range of orthotics and prosthetics solutions, including upper and lower limb prosthetics, orthotic devices, and accessories.
Enovis Corporation offers a comprehensive range of rehabilitation solutions, including physical therapy, occupational therapy, and speech therapy.
Enovis Corporation designs and manufactures surgical implants, including joint replacement implants, spinal implants, and orthobiologics.
Enovis Corporation provides a range of bracing and support solutions, including spinal bracing, knee bracing, and ankle bracing.
Enovis Corporation offers a range of wound care solutions, including dressings, debridement, and negative pressure wound therapy.
Enovis Corporation designs and manufactures surgical instruments, including orthopedic, neurosurgical, and spinal instruments.
Enovis Corporation operates in a niche market with limited substitutes, but there are some alternatives available to customers.
Enovis Corporation has a diverse customer base, which reduces the bargaining power of individual customers.
Enovis Corporation has a moderate level of dependence on its suppliers, but it has implemented strategies to mitigate supply chain risks.
The medical technology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services.
The medical technology industry is highly competitive, and Enovis Corporation faces intense rivalry from established players and new entrants.
| Value | |
|---|---|
| Debt Weight | 13.56% |
| Debt Cost | 4.59% |
| Equity Weight | 86.44% |
| Equity Cost | 14.31% |
| WACC | 12.99% |
| Leverage | 15.69% |
Value: 2.7
Growth: 8.6
Quality: 4.1
Yield: 0.0
Momentum: 7.0
Volatility: 5.0
1-Year Total Return ->
Value: 4.2
Growth: 5.0
Quality: 3.5
Yield: 0.0
Momentum: 6.5
Volatility: 6.0
1-Year Total Return ->
Value: 1.6
Growth: 5.4
Quality: 5.1
Yield: 0.0
Momentum: 9.0
Volatility: 3.3
1-Year Total Return ->
Value: 3.8
Growth: 6.7
Quality: 6.0
Yield: 0.0
Momentum: 3.5
Volatility: 4.0
1-Year Total Return ->
Value: 5.2
Growth: 4.0
Quality: 5.0
Yield: 2.0
Momentum: 3.0
Volatility: 4.7
1-Year Total Return ->
Value: 8.8
Growth: 1.6
Quality: 3.9
Yield: 0.0
Momentum: 1.5
Volatility: 4.7
1-Year Total Return ->